Arix Bioscience takes stake in Aussie fibrosis specialist Pharmaxis
Arix led a A$24mln (£13.4mln) primary placing and will invest A$14.2mln itself in two tranches
Company
Syntara Ltd
ASX:PXS
Syntara Ltd is a clinical-stage drug development company focused on the development of novel therapeutics aimed at correcting extracellular matrix (ECM) dysfunction. This will lead to positive outcomes in a range of diseases with high unmet need, including haematological malignancies such as myelofibrosis and myelodysplastic syndrome, chronic fibrosis (including skin scarring, pulmonary fibrosis, chronic kidney disease, NASH and cardiac fibrosis) and neuroinflammation.
175 stories · page 6 of 9
Investments and investor services
FTSE 100 closes higher, supported by gains in oil giants as crude prices rise
At the close, the UK blue chip index was 4.68 points higher at 7,663.78, just below the session peak of 7,681.86, having recovered from a low of 7,636.60
Investments and investor services
Pharmaxis secures $24 million at premium to support partnering negotiations
The capital raising was priced at a premium to the last traded share price.
Pharmaxis enters trading halt ahead of share placement
The company plans to raise funds by way of a share placement.
Pharmaxis powering ahead with phase I LOXL2 studies
The company finished the June quarter with just over $31 million in cash.
Pharmaxis phase I trial attracts interest from multiple pharmaceutical companies
Final stages of phase I studies and phase II enabling toxicity studies are due to complete in Q3 2018.
Pharmaxis boosts cash position securing sustainable future
Large pharma companies are being attracted to the company’s drug development portfolio.
Pharmaxis outlines share price catalysts for 2018
Value inflection points are expected in a number of programs.
Pharmaxis strengthens balance sheet with $15 million milestone payment
The payment has unlocked the full deal potential of $625 million.
Pharmaxis secures further Australian government reimbursement for Bronchitol
Pharmaxis is a global leader in drug development for fibrosis and inflammation.
Archive
Proactive news snapshot: Synairgen, Iofina, Atlantis Resources …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Scancell Holdings soars after "stunning endorsement" of its ImmunoBody platform
Cancer Research UK was immensely impressed with the company and its technology
Synairgen shoots higher on new terms for fibrosis collaboration
Synairgen will retain a 17% interest in any partnership across all fibrotic indications
Pharmaxis takes full control of collaboration on LOXL2 inhibitors and expands scientific program
The program scope has been doubled to encompass two lead candidates.
Pharmaxis boosts its drug discovery ranks
The company has made three new hires including a head of chemistry.
Lots of potential for Synairgen in fibrosis, suggests broker finncap
A Phase I clinical trial is to start later this year for the LOXL-2 inhibitor
Pharmaxis and collaborator Synairgen advance towards human clinical studies
The Pharmaxis drug discovery group has developed a number of selective small molecule inhibitors.
Pharmaxis' largest shareholder BVF Partners LP lifts stake
The Pharmaxis register contains international specialist biotech investors.
Pharmaxis to receive cash injection as Boehringer Ingelheim initiates new trials
Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis.
Pharmaxis receives support for expanded reimbursement of its drug Bronchitol®
Bronchitol® is an inhaled dry powder for the treatment of cystic fibrosis.